UF Health, OneFlorida Consortium to Evaluate Blood Thinners As COVID-19 Treatment

The National Institutes of Health has launched two of three adaptive clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19.

Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world, including University of Florida Health and the OneFlorida Clinical Research Consortium. The studies will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe cases of the disease.

“Health systems around the state are combining their efforts to be a key part of this clinical trial,” said Eileen Handberg, Ph.D., ARNP, a professor in cardiology at UF Health and site principal investigator for the ACTIV-4 Antithrombotic Outpatient trial. “Our centralized administration and OneFlorida’s extensive network of health partners in Florida and around the country make us an ideal site for handling the kind of rapid recruitment needed for COVID-19 trials like ACTIV-4.”

Learn more about UF Health, OneFlorida Consortium to Evaluate Blood Thinners As COVID-19 Treatment.